Marillion Pharmaceuticals and Bracco Imaging, part of the Bracco Group, have entered into a license agreement granting Marillion exclusive worldwide rights to complete clinical development and to commercialize Bracco’s 177Lu-AMBA for the treatment of hormone-resistant prostate and metastatic breast cancers.
 
Bracco’s 177Lu-AMBA is a targeted radiotherapeutic that utilizes an innovative receptor-based technology to home in on tumor cells and spare normal tissues. Early clinical trials have shown that these metastases may also be effectively targeted by 177Lu-AMBA, according to Zahed Subhan, MD, CEO of Marillion, based in Exton, Pa.